PD30-03 PREDICTING UNFAVORABLE PROSTATE CANCER IN ACTIVE SURVEILLANCE CANDIDATES TREATED WITH RADICAL PROSTATECTOMY: A POPULATION-BASED STUDY

2015 ◽  
Vol 193 (4S) ◽  
Author(s):  
Nicola Fossati ◽  
Justin K. Lee ◽  
Quoc-Dien Trinh ◽  
Jesse Sammon ◽  
Akshay Sood ◽  
...  
2015 ◽  
Vol 193 (4S) ◽  
Author(s):  
Nicola Fossati ◽  
Justin K. Lee ◽  
Quoc-Dien Trinh ◽  
Jesse Sammon ◽  
Akshay Sood ◽  
...  

BMJ Open ◽  
2019 ◽  
Vol 9 (12) ◽  
pp. e033944
Author(s):  
Oskar Bergengren ◽  
Hans Garmo ◽  
Ola Bratt ◽  
Lars Holmberg ◽  
Eva Johansson ◽  
...  

ObjectiveKnowledge about factors influencing choice of and adherence to active surveillance (AS) for prostate cancer (PC) is scarce. We aim to identify which factors most affected choosing and adhering to AS and to quantify their relative importance.Design, setting and participantsIn 2015, we sent a questionnaire to all Swedish men aged ≤70 years registered in the National Prostate Cancer Register of Sweden who were diagnosed in 2008 with low-risk PC and had undergone prostatectomy, radiotherapy or started on AS.Outcome measurements and statistical analysisLogistic regression was used to calculate ORs with 95% CIs for factors potentially affecting choice and adherence to AS.Results1288 out of 1720 men (75%) responded, 451 (35%) chose AS and 837 (65%) underwent curative treatment. Of those starting on AS, 238 (53%) diverted to treatment within 7 years. Most men (83%) choose AS because ‘My doctor recommended AS’. Factors associated with choosing AS over treatment were older age (OR 1.81, 95% CI 1.29 to 2.54), a Charlson Comorbidity Index >2 (OR 1.50, 95% CI 1.06 to 2.13), being unaccompanied when notified of the cancer diagnosis (OR 1.45, 95% CI 1.11 to 1.89). Men with a higher prostate-specific antigen (PSA) at the time of diagnosis were less likely to adhere to AS (OR 0.26, 95% CI 0.10 to 0.63). The reason for having treatment after initial AS was ‘the PSA level was rising’ in 55% and biopsy findings in 36%.ConclusionsA doctor’s recommendation strongly affects which treatment is chosen for men with low-risk PC. Rising PSA values were the main factor for initiating treatment for men on AS. These findings need be considered by healthcare providers who wish to increase the uptake of and adherence to AS.


2013 ◽  
Vol 113 (4) ◽  
pp. 541-547 ◽  
Author(s):  
Martin Andreas Røder ◽  
Klaus Brasso ◽  
Ib Jarle Christensen ◽  
Jørgen Johansen ◽  
Niels Christian Langkilde ◽  
...  

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e16553-e16553
Author(s):  
Grace L. Lu-Yao ◽  
Jianming He ◽  
Veda N. Giri ◽  
Ann Klassen

e16553 Background: This population-based study assesses the relationship between insurance status and patterns of prostate cancer diagnosis and treatment among men under age 65. Methods: Using the Surveillance, Epidemiology, and End Results (SEER) database, we identified 114,871 prostate cancer patients who were diagnosed before 65 between January 2007 and December 2013. Insurance type was classified as uninsured (3.1%), Medicaid (5.1%) and other including private insurance and coverage from the military or Veterans Affairs (91.8%). We used logistic regression model to quantify the relative risk of being diagnosed with metastasis or regional disease, and the relative likelihood of receiving radical prostatectomy or radiotherapy among those with localized cancer adjusted by, age, race, marital status, region, and diagnosis period. Results: Medicaid or uninsured patients are more likely to have late diagnosis (diagnosed with positive lymph node or metastasis) than patients with non-Medicaid insurance (Table 1). Among men diagnosed with localized prostate cancer, Medicaid and uninsured patients are less likely to receive prostatectomy. Medicaid patients are more likely to have radiotherapy than un-insured (see table). Conclusions: Compared with patients with non-Medicaid insurance, Medicaid and uninsured patients are more likely have late diagnosis and less likely to have radical prostatectomy for localized cancer, after accounting for differences in age, race, marital status, region, and diagnosis period. [Table: see text]


2015 ◽  
Vol 193 (4S) ◽  
Author(s):  
Patrick O. Richard ◽  
Shabbir Alibhai ◽  
David Urbach ◽  
Neil E. Fleshner ◽  
Narhari Timilshina ◽  
...  

2016 ◽  
Vol 15 (3) ◽  
pp. e167
Author(s):  
D. Robinson ◽  
H. Garmo ◽  
I. Franck Lissbrant ◽  
P. Nilsson ◽  
A. Widmark ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document